AMI-1

• Description:

  AMI-1 is a potent, cell-permeable and reversible inhibitor of protein arginine N-methyltransferases (PRMTs), with IC50s of 8.8 μM and 3.0 μM for human PRMT1 and yeast-Hmt1p, respectively. AMI-1 exerts PRMTs inhibitory effects by blocking peptide-substrate binding[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Histone Methyltransferase

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/AMI-1.html

• Concentration:

  10mM

• Purity:

  98.0

• Solubility:

  H2O : 62.5 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C(NC1=CC2=CC(S(=O)(O[Na])=O)=CC(O)=C2C=C1)NC3=CC4=CC(S(=O)(O[Na])=O)=CC(O)=C4C=C3

• Molecular Formula:

  C21H14N2Na2O9S2

• Molecular Weight:

  548.45

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Zhang, B., et al. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3. Oncotarget. 2015 Sep 8;6 (26) :22799-811.|[2]Baolai Zhang, et al. Arginine Methyltransferase inhibitor-1 Inhibits Sarcoma Viability in vitro and in vivo. Oncol Lett. 2018 Aug;16 (2) :2161-2166.|[3]Donghang Cheng, et al. Small Molecule Regulators of Protein Arginine Methyltransferases. J Biol Chem. 2004 Jun 4;279 (23) :23892-9.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  PRMT1

• Citation 01:

  Cell Death Dis. 2023 Sep 22;14 (9) :624.|Cell Death Dis. 2024 Nov 11;15 (11) :814.|Genes Dis. 2023 Mar 28;10 (6) :2622-2638.|Nat Commun. 2023 Feb 23;14 (1) :1011.|Cell Rep. 2024 Aug 22;43 (9) :114662.|Cell Rep. 2024 Jul 24;43 (8) :114537.

• CAS Number:

  [20324-87-2]